Abstract
Dendritic nanoparticles have been developed with auspicious properties like high loading capacity for guest molecules, low polydispersity and tunable end groups. Demonstrating increased cellular uptake and bypassed efflux transporters, dendritic nanoparticles may offer new treatment options for therapy-resistant diseases. New core-shell architectures address the drawbacks of initial approaches. Especially tecto-dendrimers, bearing low-radii dendrimers on the surface of a bigger dendrimer, as well as the core-multishell architectures with an alkyl inner shell and a monomethylpoly(ethylene glycol) outer shell, gained interest for dermatotherapy. Moreover, the integration of e.g. pH labile groups into dendritic nanoparticles may offer triggered drug release. However, before declaring dendritic nanoparticles as an ultimate drug delivery system for skin penetration, dendritic nanoparticles need to prove their efficacy and safety in non-clinical, and subsequently in clinical studies.
Here, we review major characteristics of human skin, and thus target structures for topical drug delivery systems. Focusing on the use as in vitro test system, we summarize the features of reconstructed human skin. Since drug delivery systems are intended to be applied to diseased skin, we additionally review latest insights into disease-related changes in the highly prevalent skin diseases such as atopic dermatitis, and cutaneous squamous cell carcinoma, as well as in their respective human cell-based skin disease models.
We will conclude with the proposal of an integrated test strategy to promote the introduction of dendritic nanoparticles into medicinal products.
Keywords: Atopic dermatitis, dendrimers, drug delivery systems, non-melanoma skin cancer, reconstructed human skin, skin penetration, tight junctions.
Current Pharmaceutical Design
Title:Dendritic Nanoparticles for Cutaneous Drug Delivery - Testing in Human Skin and Reconstructed Human Skin
Volume: 21 Issue: 20
Author(s): Christian Zoschke, Priscila Schilrreff, Eder L. Romero, Johanna M. Brandner and Monika Schafer- Korting
Affiliation:
Keywords: Atopic dermatitis, dendrimers, drug delivery systems, non-melanoma skin cancer, reconstructed human skin, skin penetration, tight junctions.
Abstract: Dendritic nanoparticles have been developed with auspicious properties like high loading capacity for guest molecules, low polydispersity and tunable end groups. Demonstrating increased cellular uptake and bypassed efflux transporters, dendritic nanoparticles may offer new treatment options for therapy-resistant diseases. New core-shell architectures address the drawbacks of initial approaches. Especially tecto-dendrimers, bearing low-radii dendrimers on the surface of a bigger dendrimer, as well as the core-multishell architectures with an alkyl inner shell and a monomethylpoly(ethylene glycol) outer shell, gained interest for dermatotherapy. Moreover, the integration of e.g. pH labile groups into dendritic nanoparticles may offer triggered drug release. However, before declaring dendritic nanoparticles as an ultimate drug delivery system for skin penetration, dendritic nanoparticles need to prove their efficacy and safety in non-clinical, and subsequently in clinical studies.
Here, we review major characteristics of human skin, and thus target structures for topical drug delivery systems. Focusing on the use as in vitro test system, we summarize the features of reconstructed human skin. Since drug delivery systems are intended to be applied to diseased skin, we additionally review latest insights into disease-related changes in the highly prevalent skin diseases such as atopic dermatitis, and cutaneous squamous cell carcinoma, as well as in their respective human cell-based skin disease models.
We will conclude with the proposal of an integrated test strategy to promote the introduction of dendritic nanoparticles into medicinal products.
Export Options
About this article
Cite this article as:
Zoschke Christian, Schilrreff Priscila, Romero L. Eder, Brandner M. Johanna and Schafer- Korting Monika, Dendritic Nanoparticles for Cutaneous Drug Delivery - Testing in Human Skin and Reconstructed Human Skin, Current Pharmaceutical Design 2015; 21 (20) . https://dx.doi.org/10.2174/1381612821666150428142515
DOI https://dx.doi.org/10.2174/1381612821666150428142515 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
Current Cancer Drug Targets Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy
Current Medicinal Chemistry Gender Effects on Rat Metabolism of AMG 900, an Orally Available Small Molecule Aurora Kinase Inhibitor
Drug Metabolism Letters Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer
Current Topics in Medicinal Chemistry Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Bladder Cancer: A Simple Model Becomes Complex
Current Genomics HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Anti-Proliferative Activity of Standardized Methanol Extract of Coscinium fenestratum and Its Major Constituent, Berberine, Against Nasopharyngeal Carcinoma Cells
The Natural Products Journal Chemokines and Breast Cancer: A Gateway to Revolutionary Targeted Cancer Treatments?
Current Medicinal Chemistry Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Synthesis and In Vitro Anticancer Activity of Novel 2-((3-thioureido)carbonyl) phenyl Acetate Derivatives
Letters in Drug Design & Discovery Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer
Current Cancer Drug Targets The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Predicting Cancer-Related MiRNAs Using Expression Profiles in Tumor Tissue
Current Pharmaceutical Biotechnology